News

Gavreto, a once-daily and oral precision therapy, will help selectively target RET alterations such as fusions and mutations irrespective of the tissue of origin. Roche’s wholly-owned member Genentech

PANS is a condition defined by sudden onset of obsessive-compulsive symptoms and/or severe eating restrictions, along with at least two other cognitive, behavioral, or neurological symptoms, according to

Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies. “Kite is committed

The FDA approval, which enables to expand the label of once-weekly Trulicity to include 3.0mg and 4.5mg doses, was based on data from the AWARD-11 phase 3 trial,

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Submitting this IND is the most important milestone the Company has met thus far in the clinical development of our

These neutralizing effects were found to be comparable to or better than those seen with antibody candidates derived from patients who had recovered from COVID-19. The data were

Both firms have worked together to develop a vaccine candidate, which applies the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s pandemic adjuvant

SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.1,2 The approval by the European Commission was

JTX-1811, which is a monoclonal antibody, is said to have been designed by Jounce Therapeutics to preferentially deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. The immunotherapy candidate’s target